Gilead Sciences Forecast, price target & analysts
Gilead Sciences Target price 2026 - Analyst rating & recommendation
Gilead Sciences Classifications & Recommendation
Gilead Sciences Price Target
| Target Price | $165.24 |
| Price | $150.11 |
| Potential | 10.08% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target Gilead Sciences 2027 . The average Gilead Sciences target price is $165.24. This is 10.08% higher than the current stock price. The highest price target is $189.00 25.91% , the lowest is $124.23 17.24% . | |
| A rating was issued by 37 analysts: 30 Analysts recommend Gilead Sciences to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2027 of 10.08% . Most analysts recommend the Gilead Sciences stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
32 Analysts have issued a sales forecast Gilead Sciences 2026 . The average Gilead Sciences sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Gilead Sciences EBITDA forecast 2026. The average Gilead Sciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
33 Gilead Sciences Analysts have issued a net profit forecast 2026. The average Gilead Sciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
33 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences EPS is
This results in the following potential growth metrics and future valuations:
Gilead Sciences...
Current Gilead Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Buy
➜
Buy
|
Unchanged | Sep 10 2026 |
| Needham |
Buy
➜
Buy
|
Unchanged | Aug 05 2026 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Aug 05 2026 |
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Aug 05 2026 |
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 29 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 27 2026 |
| Leerink Partners |
Outperform
➜
Market Perform
|
Downgrade | Jul 21 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
HSBC:
Buy
➜
Buy
|
Sep 10 2026 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Aug 05 2026 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Aug 05 2026 |
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Aug 05 2026 |
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Jul 29 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 27 2026 |
|
Downgrade
Leerink Partners:
Outperform
➜
Market Perform
|
Jul 21 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
